Jonathan D. Schwartz

9.1k total citations · 2 hit papers
60 papers, 4.7k citations indexed

About

Jonathan D. Schwartz is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jonathan D. Schwartz has authored 60 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 22 papers in Oncology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jonathan D. Schwartz's work include Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Gastric Cancer Management and Outcomes (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Jonathan D. Schwartz is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Gastric Cancer Management and Outcomes (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Jonathan D. Schwartz collaborates with scholars based in United States, Spain and United Kingdom. Jonathan D. Schwartz's co-authors include Max W. Sung, Myron Schwartz, David Ferry, Jaffer A. Ajani, Atsushi Ohtsu, David Cunningham, Yasuhiro Shimada, Yoshito Komatsu, Roberto Carlesi and Kei Muro and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Investigation.

In The Last Decade

Jonathan D. Schwartz

59 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

2014 1.7k citations H. Wilke, Kei Muro et al. The Lancet Oncology profile →
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 634 citations Andrew X. Zhu, Joon Oh Park et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan D. Schwartz United States	25	2.0k	1.9k	1.6k	1.1k	1.1k	60	4.7k
Jianming Xu China	33	3.8k 2.0×	3.0k 1.6×	1.1k 0.7×	1.1k 1.0×	1.5k 1.4×	218	6.6k
Christopher R. Garrett United States	25	2.8k 1.4×	2.4k 1.3×	718 0.5×	1.4k 1.2×	953 0.9×	50	5.3k
Allen Lee Cohn United States	38	4.7k 2.4×	2.4k 1.3×	1.2k 0.7×	1.5k 1.3×	875 0.8×	159	6.9k
Arnaud Roth Switzerland	34	3.4k 1.7×	1.8k 1.0×	661 0.4×	860 0.8×	1.3k 1.2×	115	5.1k
Ilhan Celik Germany	15	2.8k 1.4×	1.6k 0.9×	580 0.4×	749 0.7×	682 0.6×	31	3.9k
Shukui Qin China	25	1.9k 0.9×	1.5k 0.8×	544 0.3×	538 0.5×	787 0.7×	95	3.1k
Lipika Goyal United States	31	2.5k 1.3×	1.4k 0.7×	1.3k 0.8×	1.3k 1.1×	2.3k 2.1×	185	5.1k
J. Randolph Hecht United States	22	2.8k 1.4×	1.9k 1.0×	548 0.3×	949 0.8×	715 0.7×	78	4.2k
David Tougeron France	36	2.4k 1.2×	1.4k 0.7×	326 0.2×	489 0.4×	1.4k 1.3×	223	3.9k
Henry Q. Xiong United States	18	2.8k 1.4×	1.3k 0.7×	924 0.6×	1.2k 1.1×	801 0.7×	39	4.3k

Countries citing papers authored by Jonathan D. Schwartz

Since Specialization

Citations

This map shows the geographic impact of Jonathan D. Schwartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan D. Schwartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan D. Schwartz more than expected).

Fields of papers citing papers by Jonathan D. Schwartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan D. Schwartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan D. Schwartz. The network helps show where Jonathan D. Schwartz may publish in the future.

Co-authorship network of co-authors of Jonathan D. Schwartz

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan D. Schwartz. A scholar is included among the top collaborators of Jonathan D. Schwartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan D. Schwartz. Jonathan D. Schwartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sebastián, Elena, Paula Rı́o, Jean Soulier, et al.. (2025). Case Report: Eltrombopag in mosaic and gene therapy-treated patients with Fanconi anemia. Frontiers in Pediatrics. 13. 1625751–1625751.

Opbergen, Chantal J.M. van, Katie M. Stiles, Vartika Mishra, et al.. (2024). AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans. Circulation Genomic and Precision Medicine. 17(1). e004305–e004305. 22 indexed citations

Corti, Manuela, Kirsten E. Coleman, Julie Berthy, et al.. (2023). Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. Journal of Clinical Investigation. 134(1). 67 indexed citations

Long-Boyle, Janel, Donald B. Kohn, Ami J. Shah, et al.. (2023). Busulfan and subsequent malignancy: An evidence‐based risk assessment. Pediatric Blood & Cancer. 71(1). e30738–e30738. 3 indexed citations

Shah, Ami J., José Luis López Lorenzo, Susana Navarro, et al.. (2021). Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients. Blood. 138(Supplement 1). 563–563. 3 indexed citations

Moscatelli, Ilana, Elena Almarza, Axel Schambach, et al.. (2020). Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal. Molecular Therapy — Methods & Clinical Development. 20. 389–397. 6 indexed citations

Bueren, Juan A., Paula Rı́o, Susana Navarro, et al.. (2020). Mosaicism in Fanconi anemia: concise review and evaluation of published cases with focus on clinical course of blood count normalization. Annals of Hematology. 99(5). 913–924. 30 indexed citations

Yoon, Harry H., Johanna C. Bendell, Fadi S. Braiteh, et al.. (2016). Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Annals of Oncology. 27(12). 2196–2203. 98 indexed citations

Zhu, Andrew X., Joon Oh Park, Baek‐Yeol Ryoo, et al.. (2015). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 16(7). 859–870. 634 indexed citations breakdown →

10.

Brooks, Christopher, Peter R. McDonald, Jonathan D. Schwartz, et al.. (2015). SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity. Blood. 126(23). 4433–4433. 1 indexed citations

11.

Carvajal, Richard D., Michael K. Wong, John A. Thompson, et al.. (2014). A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. European Journal of Cancer. 50(12). 2099–2107. 22 indexed citations

12.

Wilke, H., Kei Muro, Eric Van Cutsem, et al.. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet Oncology. 15(11). 1224–1235. 1715 indexed citations breakdown →

13.

Zhu, Andrew X., Richard S. Finn, Mary F. Mulcahy, et al.. (2013). A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research. 19(23). 6614–6623. 122 indexed citations

14.

Rowinsky, Eric K., Jonathan D. Schwartz, Naseem J. Zojwalla, et al.. (2011). Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers. Current Drug Targets. 12(14). 2016–2033. 23 indexed citations

15.

Duignan, Inga, Erik Corcoran, Mary Jane Plym, et al.. (2011). Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models. Neoplasia. 13(1). 49–59. 14 indexed citations

16.

Shah, Gaurav, Nick Loizos, Hagop Youssoufian, Jonathan D. Schwartz, & Eric K. Rowinsky. (2010). Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α. Cancer. 116(S4). 1018–1026. 50 indexed citations

17.

Schwartz, Jonathan D., Eric K. Rowinsky, Hagop Youssoufian, Bronislaw Pytowski, & Yan Wu. (2010). Vascular endothelial growth factor receptor‐1 in human cancer. Cancer. 116(S4). 1027–1032. 69 indexed citations

18.

Schwartz, Jonathan D. & Andreas S. Beutler. (2004). Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anti-Cancer Drugs. 15(5). 439–452. 45 indexed citations

19.

Reidy‐Lagunes, Diane & Jonathan D. Schwartz. (2004). Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anti-Cancer Drugs. 15(5). 427–437. 29 indexed citations

20.

Safran, Howard, David A. Iannitti, Ramesh K. Ramanathan, et al.. (2004). Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu. Cancer Investigation. 22(5). 706–712. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact